Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

Mitogen-Activated Protein Kinase (MAPK) pathway activation has been implicated in many types of human cancer. BRAF mutations that constitutively activate MAPK signalling and bypass the need for upstream stimuli occur with high prevalence in melanoma, colorectal carcinoma, ovarian cancer, papillary t...

Full description

Bibliographic Details
Main Authors: Alastair J King, Marc R Arnone, Maureen R Bleam, Katherine G Moss, Jingsong Yang, Kelly E Fedorowicz, Kimberly N Smitheman, Joseph A Erhardt, Angela Hughes-Earle, Laurie S Kane-Carson, Robert H Sinnamon, Hongwei Qi, Tara R Rheault, David E Uehling, Sylvie G Laquerre
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3701070?pdf=render

Internet

http://europepmc.org/articles/PMC3701070?pdf=render

Similar Items